Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

British Journal of Cancer

Volumn 103, Issue 10, 2010, Pages 1524-1528

  Garcia Alfonso P ^a   Muoz Martin A J ^a   Alvarez Suarez, S ^a   Jerez Gilarranz, Y ^a   Riesco Martinez, M ^a   Khosravi, P ^a   Martin, M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

bevacizumab; capecitabine; combined modality treatment; irinotecan; metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; HAND FOOT SYNDROME; HUMAN; MALE; METASTASIS; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; VOMITING;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; BLOOD CELL COUNT; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CREATININE; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SELECTION;

EID: 78149466095     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605907     Document Type: Article

References (20)

1. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R (2004) Randomized multicenter phase II trial of two different schedules of irinotecan combined to capecitabine as first line treatment in metastatic colorectal cancer. Cancer 100: 279-287
2. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091
3. Chen E, Welch S, Krzyzanowska M, MacKay H, Knox J, Feld R, Petronis J, Blatter C, Wang L, Moore MJ (2009) A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC) [abstract e15019]. J Clin Oncol ASCO Annu Meet Proc 27: e15019
4. Ducreux M, Adenis A, Mendiboure J, François E, Boucher E, Chauffert B, Ychou M, Pierga J, Montoto-Grillot C, Conroy T, Institut Gustave Roussy, Villejuif, France; Centre Oscar Lambret, Lille, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Centre Georges-François Leclerc, Dijon, France; Centre Val d'Aurelle, Montpellier, France; Institut Curie, Paris, France; FNCLCC, Paris, France; Centre Alexis Vautrin, Nancy, France (2009) Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study) [abstract 4086]. J Clin Oncol ASCO Annu Meet Proc 27: 4086
5. Fuchs CS, Marshall J, Barrueco J (2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26: 689-690
6. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoro-pyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786
7. Garcia-Alfonso P, Muñoz-Martin A, Mendez-Ureña M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G (2009) Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer 101: 1039-1043
8. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine vs intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III trial. J Clin Oncol 19: 2282-2292
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
10. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
11. Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E (2008) Irinotecan combined with infusional 5-fluorouracil/ folinic acid or capecitabine plus celecoxib or placebo in the firstline treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19: 920-926
12. Kolinsky K, Zhang YE, Dugan U, Heimbrook D, Packman K, Higgins B (2009) Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts. Anticancer Res 29(1): 91-98
13. Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A, Depisch D (2003) Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 21: 1307-1312
14. Shen B, Stainton S, Li D, Zhu S, Pelletier N, Zioncheck TF (2004) Combination of Avastin and Xeloda synergistically inhibits colorectal tumor growth in a CoIo205 tumor xenograft model [abstract]. Proceedings of the 95th Annual Meeting of the American Association for Cancer Research, p 45, Abstract 2203; 27-31 March 2004. AACR: Orlando, FL
15. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10
16. Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, Harstrick A, Rustum YM, Vanhoefer U (2003) Capecitabine and irino-tecan as first-line chemotherapy in patients with metastatic colo-rectal cancer: results of an extended phase I study. Ann Oncol 14: 1442-1448
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92: 205-216
18. Traina TA, Theodoulou M, Feigin K, Patil S, Tan KL, Edwards C, Dugan U, Norton L, Hudis C (2008) Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 26: 1797-1802
19. Van Cutsem E, Oliveira J, ESMO Guidelines Working Group (2009) Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: 61-63
20. Van Cutsem EM, Hoff P, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun J A, Marshall J L, Mitchell E P, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL (2004) Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90: 1190-1197